TheEdgeResearch
Home / Stocks / KNTPF

Kintor Pharmaceutical Limited (KNTPF)

OTC Healthcare Biotechnology
$0.16 ▲ +0.00%
Market Cap
$76.6M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.57
52-Wk Range
0.1542-0.5708
CEO
Youzhi Tong
Country
CN
Currency
USD

Kintor Pharmaceutical Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Suzhou, JS, CN. The stock last traded at $0.16, up 0.00% on the session, giving a market capitalisation of $76.6M. On trailing twelve-month figures it carries a trailing P/E of -2.72, a net margin of -244.4%. Its beta of -0.57 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.72
Price / Sales
7.03
Price / Book
5.04
EV / EBITDA
-4.06
Gross margin
12.6%
Operating margin
-256.1%
Net margin
-244.4%
Return on equity
—
Debt / equity
1.22
Current ratio
0.26
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
123
IPO date
2020-12-11
Headquarters
Suzhou, JS, CN
About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.

Comparable companies

Kintor Pharmaceutical Limited is most often compared with the following Healthcare names:

AURXHOFBFIPHYFIUGNFMSCLFPBIGFPOLBFSCNLFSHIEFVSBC
More research on KNTPF
KNTPF technical analysis KNTPF TheEdge Score Compare against peers
Open full interactive analysis & DCF →